S Halabi

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, USA
    J Urol 176:81-6. 2006
  2. ncbi request reprint Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics and CALGB Statistical Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:1232-7. 2003
  3. ncbi request reprint Analysis of survival data with missing measurements of a time-dependent binary covariate
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biopharm Stat 13:253-70. 2003
  4. ncbi request reprint The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Urol 177:531-4. 2007
  5. doi request reprint Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics and the Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 27705, USA
    Urol Oncol 26:300-7. 2008
  6. ncbi request reprint Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583
    Susan Halabi
    Department of Biostatistics and Bioinformatics and CALGB Statistical Center, Duke University, Durham, NC 27710, USA
    J Clin Oncol 21:490-5. 2003
  7. doi request reprint Pain predicts overall survival in men with metastatic castration-refractory prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University, and Cancer and Leukemia Group B Statistical Center, Durham, NC, USA
    J Clin Oncol 26:2544-9. 2008
  8. ncbi request reprint Sample size determination for comparing several survival curves with unequal allocations
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Box 3958, Durham, NC 27710, USA
    Stat Med 23:1793-815. 2004
  9. pmc Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Rd, Durham, NC 27705, USA
    J Clin Oncol 27:2766-71. 2009
  10. ncbi request reprint Factors associated with repeat mammography screening
    S Halabi
    Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Fam Pract 49:1104-12. 2000

Detail Information

Publications57

  1. ncbi request reprint Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Road, Durham, NC 27705, USA
    J Urol 176:81-6. 2006
    ..We determined if age is a prognostic factor of clinical outcomes, specifically overall survival, disease-free survival and progression-free survival in men with hormone refractory prostate cancer...
  2. ncbi request reprint Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics and CALGB Statistical Center, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:1232-7. 2003
    ..To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients (HRPC)...
  3. ncbi request reprint Analysis of survival data with missing measurements of a time-dependent binary covariate
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Biopharm Stat 13:253-70. 2003
    ..An example from the Systolic Hypertension in the Elderly Program was used. Inference on the effect of systolic blood pressure on survival is strongly affected by the number and timing of systolic blood measurements...
  4. ncbi request reprint The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Urol 177:531-4. 2007
    ....
  5. doi request reprint Statistical considerations for the design and analysis of Phase III clinical trials in prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics and the Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 27705, USA
    Urol Oncol 26:300-7. 2008
    ....
  6. ncbi request reprint Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583
    Susan Halabi
    Department of Biostatistics and Bioinformatics and CALGB Statistical Center, Duke University, Durham, NC 27710, USA
    J Clin Oncol 21:490-5. 2003
    ....
  7. doi request reprint Pain predicts overall survival in men with metastatic castration-refractory prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University, and Cancer and Leukemia Group B Statistical Center, Durham, NC, USA
    J Clin Oncol 26:2544-9. 2008
    ..The objective of this study was to determine whether men with CRPC who had higher pain interference scores at baseline had worse clinical outcomes compared with men who had lower pain scores...
  8. ncbi request reprint Sample size determination for comparing several survival curves with unequal allocations
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Box 3958, Durham, NC 27710, USA
    Stat Med 23:1793-815. 2004
    ..80 when 50 per cent of the patients are allocated to the treatment group with the smallest hazard...
  9. pmc Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, 2424 Erwin Rd, Durham, NC 27705, USA
    J Clin Oncol 27:2766-71. 2009
    ..To explore whether progression-free survival (PFS) or biochemical PFS can be used as a predictor of overall survival (OS) and to investigate the dependence between PFS and OS in men with castrate-resistant prostate cancer...
  10. ncbi request reprint Factors associated with repeat mammography screening
    S Halabi
    Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Fam Pract 49:1104-12. 2000
    ....
  11. ncbi request reprint Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27705, USA
    Cancer 110:1478-84. 2007
    ..For this reason, the correlation between an elevated body mass index (BMI) and clinical outcomes in patients with metastatic, castration-recurrent prostate cancer (CRPC) was evaluated...
  12. ncbi request reprint Impact of race on survival in men with metastatic hormone-refractory prostate cancer
    Susan Halabi
    Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Urology 64:212-7. 2004
    ..To determine whether blacks with hormone-refractory prostate cancer have shorter survival compared with whites with the same disease...
  13. ncbi request reprint The impact of abnormal mammograms on psychosocial outcomes and subsequent screening
    I M Lipkus
    Duke University Medical Center, Cancer Prevention, Detection, and Control Research Program, Durham, NC 27701, USA
    Psychooncology 9:402-10. 2000
    ..Women who had an abnormal mammogram within 2 years prior to the baseline interview were more likely to be on schedule for mammography, compared with women who never had an abnormal mammogram...
  14. ncbi request reprint No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina
    Johnathan M Lancaster
    Department of Obstetrics and Gynecology Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Epidemiol Biomarkers Prev 12:226-7. 2003
  15. ncbi request reprint Anthropometric measurements and epithelial ovarian cancer risk in African-American and White women
    Cathrine Hoyo
    Department of Community and Family Medicine, Duke University Medical Center, 2424 Erwin Rd, Hock Plaza, Ste 602, Durham, NC 27710, USA
    Cancer Causes Control 16:955-63. 2005
    ..0; 95% CI = 0.7-1.4). These findings support the hypothesis that obesity is an important risk factor of ovarian cancer among African-Americans and Whites and also suggest that height may be a risk factor specific to African-Americans...
  16. ncbi request reprint Women's interest in chemoprevention for breast cancer
    L A Bastian
    the Center for Health Services Research in Primary Care, Durham Veterans Affairs Medical Center, 508 Fulton St (152, Durham, NC 27705, USA
    Arch Intern Med 161:1639-44. 2001
    ..CONCLUSION: Women's interest in chemoprevention might arise more from worries about getting breast cancer than from their objective risk factors...
  17. ncbi request reprint Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk
    Monique A Spillman
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University, DUMC Box 3079, Durham, NC 27710, USA
    Gynecol Oncol 97:543-9. 2005
    ..It has been suggested that the 6A allele of the type I TGFbeta receptor (TGFbetaR1) polyalanine repeat tract polymorphism may increase susceptibility to various types of cancer including ovarian cancer...
  18. ncbi request reprint Prognostic factors in early-onset epithelial ovarian cancer: a population-based study
    J M Schildkraut
    Department of Cancer Prevention, Detection, and Control Research Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Obstet Gynecol 95:119-27. 2000
    ..To investigate the clinical prognostic factors that influence ovarian cancer survival in women with early-onset epithelial ovarian cancer using population-based data...
  19. doi request reprint The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer
    A J Armstrong
    Duke Comprehensive Cancer Center, Duke University, Durham, NC 27705, USA
    Prostate Cancer Prostatic Dis 12:88-93. 2009
    ..There was evidence of potential hemodilution of PSA and alkaline phosphatase levels in obese men...
  20. pmc Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women
    Patricia G Moorman
    Department of Community and Family Medicine, Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, NC 27705, USA
    Am J Epidemiol 167:1059-69. 2008
    ..Findings suggest that associations between ovarian cancer and reproductive characteristics vary by menopausal status. Additional research is needed to further elucidate risk factors for postmenopausal disease...
  21. ncbi request reprint Menopausal hormones and risk of ovarian cancer
    Patricia G Moorman
    Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Am J Obstet Gynecol 193:76-82. 2005
    ..The objective of this study was to determine if use of menopausal hormones was associated with ovarian cancer and if risk varied by type of hormone used...
  22. pmc A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer
    Andrew J Armstrong
    Duke Comprehensive Cancer Center and Duke Prostate Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27710, USA
    Clin Cancer Res 16:3057-66. 2010
    ....
  23. ncbi request reprint Analgesic drug use and risk of ovarian cancer
    Joellen M Schildkraut
    Duke Comprehensive Cancer Center, Cancer Prevention, Detection and Control Research Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Epidemiology 17:104-7. 2006
    ..Previous epidemiologic research suggests that analgesic use may reduce the risk of ovarian cancer, although results are not consistent...
  24. doi request reprint The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
    Andrew J Armstrong
    Division of Medical Oncology, Department of Medicine, DUMC, Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, NC 27715, USA
    Eur J Cancer 46:517-25. 2010
    ....
  25. doi request reprint Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup
    Joellen M Schildkraut
    Department of Community and Family Medicine, Duke University Medical Center, Box 2949, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 17:585-93. 2008
    ..The objective of this study was to determine whether cyclin E overexpression defines an etiologically distinct subgroup of ovarian cancer...
  26. ncbi request reprint Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer
    Joellen M Schildkraut
    Department of Community and Family Medicine, Duke University Medical Center, Box 2949, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 16:473-80. 2007
    ..Two trinucleotide repeat polymorphisms have been described in exon 1 of the androgen receptor (AR) gene that may affect its function. Previous studies of ovarian cancer and AR repeat polymorphisms have been inconsistent...
  27. pmc A tailored intervention to aid decision-making about hormone replacement therapy
    Colleen M McBride
    The Comprehensive Cancer Center, Duke University Medical Center, Durham, NC 27710 2949, USA
    Am J Public Health 92:1112-4. 2002
  28. ncbi request reprint Antidepressant medication use [corrected] and risk of ovarian cancer
    Patricia G Moorman
    Cancer Prevention, Detection, and Control Research Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Obstet Gynecol 105:725-30. 2005
    ..The objective of this paper was to evaluate whether women with ovarian cancer were more likely to report past use of antidepressants than control women...
  29. ncbi request reprint Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States)
    Patricia G Moorman
    Cancer Prevention, Detection, and Control Research Program, Department of Community and Family Medicine, Duike Universiti Medical Center, Durham, NC 27710, USA
    Cancer Causes Control 13:807-11. 2002
    ..To compare two methods for calculating lifetime ovulatory cycles (LOC) to determine if more detailed menstrual cycle information results in stronger associations with ovarian cancer...
  30. ncbi request reprint The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480
    Daniel J George
    Divisions of Urology and Medical Oncology, Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 2771, USA
    Clin Cancer Res 11:1815-20. 2005
    ..In order to evaluate its prognostic significance in metastatic HRCaP patients, we measured IL-6 in plasma collected at baseline from patients in a large cooperative group study [Cancer and Leukemia Group B 9480 (CALGB 9480)]...
  31. ncbi request reprint Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers
    Andrew Berchuck
    Division of Gynecologic Oncology, Duke University Medical Center, Box 3079, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 13:2141-7. 2004
    ..In this study, we sought to determine whether this polymorphism affects ovarian cancer risk...
  32. ncbi request reprint Age at natural menopause and the risk of epithelial ovarian cancer
    J M Schildkraut
    Program for Prevention, Detection, and Control Research, Duke Comprehensive Cancer Center, Durham, North Carolina 27710, USA
    Obstet Gynecol 98:85-90. 2001
    ..To investigate the relationship between age at natural menopause and risk of developing epithelial ovarian cancer...
  33. pmc The importance of identifying and validating prognostic factors in oncology
    Susan Halabi
    Department of Biostatistics and Bioinformatics and the Cancer and Leukemia Group B Statistical Center, Duke University Medical Center, Durham, NC 27705, USA
    Semin Oncol 37:e9-18. 2010
    ..We illustrate the concepts within the framework of published and ongoing phase III trials in oncology...
  34. ncbi request reprint Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study
    Ellis G Levine
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263 0001, USA
    Cancer 94:665-72. 2002
    ....
  35. doi request reprint p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Urology 71:933-7. 2008
    ..It has been hypothesized that abnormal p53 protein expression is associated with a worse prognosis after radiation (RT) and androgen suppression therapy (AST). This hypothesis was prospectively tested...
  36. ncbi request reprint Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
    Mary Ellen Taplin
    University of Massachusetts Memorial Health Center, Department of Oncology, 55 Lake Ave North, Worcester, MA 01655, USA
    J Clin Oncol 21:2673-8. 2003
    ..Bone marrow specimens containing prostate tumor were obtained from men undergoing antiandrogen withdrawal for AR sequence analysis and clinical correlation. Materials and..
  37. doi request reprint Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  38. ncbi request reprint Second-line chemotherapy for advanced hormone-refractory prostate cancer
    Edward G Garmey
    ArQule Inc, Woburn, MA 01801 5140, USA
    Clin Adv Hematol Oncol 6:118-22, 127-32. 2008
    ..To date, only one phase III randomized clinical trial has been completed in this setting and no therapies are FDA-approved. We review here the entirety of phase II and III data evaluating chemotherapy agents in second-line HRPC...
  39. ncbi request reprint A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
    Robert S Sandler
    Department of Medicine, University of North Carolina, Chapel Hill 27599 7555, USA
    N Engl J Med 348:883-90. 2003
    ..Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers...
  40. ncbi request reprint Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480
    Eric J Small
    Comprehensive Cancer Center, University of California San Francisco, 1600 Devisadero Street, Third Floor, San Francisco, CA 94115, USA
    J Clin Oncol 20:3369-75. 2002
    ..To test the hypothesis that the efficacy and toxicity of suramin in the treatment of patients with hormone-refractory prostate cancer was dose dependent...
  41. ncbi request reprint Effects of a mammography decision-making intervention at 12 and 24 months
    Barbara K Rimer
    Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland 20852, USA
    Am J Prev Med 22:247-57. 2002
    ..Numerous groups have called for informed decision making about mammography, but few programs have resulted. Our research is intended to fill this gap...
  42. pmc Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 71:9-15. 2008
    ..5 Tesla endorectal magnetic resonance imaging (eMRI) was associated with the risk of recurrence after radiation (RT) and 6 months of AST...
  43. ncbi request reprint A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813
    William K Oh
    Lank Center for Geritourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 98:2592-8. 2003
    ..The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor (G-CSF) support in patients with hormone-refractory prostate carcinoma...
  44. ncbi request reprint Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study
    Charles J Ryan
    Urologic Oncology Program, University of California, San Francisco, California 94143, USA
    Clin Cancer Res 13:2030-7. 2007
    ..Ketoconazole is used as an inhibitor of adrenal androgen synthesis in men with androgen-independent prostate cancer. This study analyzes the relationship between pretreatment androgen levels and outcome following ketoconazole treatment...
  45. ncbi request reprint Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study
    Mary Ellen Taplin
    Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Urology 66:386-91. 2005
    ..Plasma CgA levels in patients with prostate cancer may reflect the extent of the tumor neuroendocrine phenotype...
  46. ncbi request reprint Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:8109-13. 2005
    ..We assessed factors predicting a successful tumor harvest from bone marrow biopsies (BMBx) in castration-resistant metastatic prostate cancer patients...
  47. ncbi request reprint 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901
    Asim Amin
    Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
    Urol Oncol 22:398-403. 2004
    ..9-nitrocamptothecin (9-NC) a novel, oral camptothecin analogue was tested as second line chemotherapy for patients with progressive hormone refractory prostate cancer...
  48. ncbi request reprint Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480
    Peter A Humphrey
    Washington University Medical Center, St Louis, MO 63110, USA
    Clin Genitourin Cancer 4:269-74. 2006
    ..Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma...
  49. ncbi request reprint Activities and accomplishments of the cancer and leukemia group B genitourinary committee
    Eric J Small
    University of California San Francisco, San Francisco, California, USA
    Clin Cancer Res 12:3596s-600s. 2006
    ..In addition to these areas, future work of the committee will include further development of therapy for earlier-stage prostate cancer patients and bladder cancer patients...
  50. ncbi request reprint Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma
    Brian I Rini
    University of California at San Francisco, San Francisco, California 94115, USA
    Clin Cancer Res 10:2584-6. 2004
    ..A Phase III trial is now being conducted randomizing untreated, metastatic clear cell RCC patients to IFN-alpha alone or IFN-alpha plus Avastin...
  51. ncbi request reprint A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008
    Walter M Stadler
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA
    Cancer 107:1273-9. 2006
    ..The objective of this study was to verify previous reports of activity with gemcitabine plus a fluoropyrimidine in patients with metastatic renal cell cancer in a multiinstitutional setting...
  52. ncbi request reprint Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583)
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California San Francisco, 1600 Divisadero St, Room A 718, San Francisco, CA 94115, USA
    J Clin Oncol 22:1025-33. 2004
    ..Thereafter, adrenal androgen ablation with agents such as ketoconazole (K) is commonly utilized. The therapeutic effect of AAWD alone was compared with simultaneous AAWD and K therapy...
  53. ncbi request reprint Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:537-56. 2004
    ..To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA)...
  54. ncbi request reprint Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer
    Susan Halabi
    J Clin Oncol 23:2434-5; author reply 2435. 2005
  55. ncbi request reprint Overview of bladder cancer trials in the Cancer and Leukemia Group B
    Eric J Small
    Department of Medicine, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 97:2090-8. 2003
    ..Novel agents, including arsenic trioxide and trastuzumab (Herceptin; Genentech, Inc., South San Francisco, CA), are being evaluated as secondline therapy in patients with advanced TCC who have disease progression after frontline therapy...
  56. ncbi request reprint Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study
    Brian I Rini
    Department of Medicine, University of California San Francisco Cancer Center, San Francisco, California, USA
    Biol Blood Marrow Transplant 12:778-85. 2006
    ..A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC...
  57. pmc Circulating levels of inflammatory cytokines and risk of colorectal adenomas
    Sangmi Kim
    Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, North Carolina 27599 7555, USA
    Cancer Res 68:323-8. 2008
    ..56 (95% CI, 1.03-2.36) and 1.66 (95% CI, 1.10-2.52), respectively. Our findings indicate that systemic inflammation might be involved in the early development of colorectal neoplasia...